A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/08 → 12/31/14

Funding

  • Wyeth Pharmaceuticals Inc: $60,038.00